Background: The aim of the study was to compare the WHO and RECIST criteria of esophageal carcinoma chemotherapy response. Material/Methods: Neoadjuvant chemotherapy was applied in a group of 52 patients with esophageal carcinoma. CT examination of the esophagus was performed in all of them before and after the appropriate course of therapy and chemotherapy response was assessed according to both WHO and RECIST criteria. The results were analyzed using the statistical software Statistica PL 5.0. Results: Complete response was found in 8 patients according to both WHO and RECIST criteria. Partial response was found in 8 patients according to WHO criteria and in 19 patients according to RECIST criteria. Stabile disease was found in 32 patients according to WHO criteria and in 20 patients according to RECIST criteria. Progression of the disease was found in 4 patients according to WHO criteria and in 5 according to RECIST. Eleven patients classified as having stabilization of the disease according to WHO criteria were classified as having partial response according to RECIST criteria. One patient classified as having stabilization of the disease according to WHO criteria was classified as having progression according to RECIST criteria. The difference was statistically significant (p=0.012). Conclusions: There are statistically significant differences between the WHO and RECIST classifications of chemotherapy response in esophageal carcinoma. The classification system must be determined when chemotherapy response is assessed. Determining which one, WHO or RECIST, is more suitable for assessing chemotherapy response of esophageal carcinoma requires additional study, including an evaluation of the survival rate in responders according to both systems.
keywords in english:
esophageal carcinoma, neoadjuvant chemotherapy, WHO criteria, RECIST criteria
Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa